MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamainternmed.2020.6319

Медицинская библиотека · JAMA internal medicine · 2021

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.

Abella Benjamin S, Jolkovsky Eliana L, Biney Barbara T, Uspal Julie E, Hyman Matthew C, Frank Ian, Hensley Scott E, Gill Saar, Vogl Dan T, Maillard Ivan, Babushok Daria V, Huang Alexander C, Nasta Sunita D, Walsh Jennifer C, Wiletyo E Paul, Gimotty Phyllis A, Milone Michael C, Amaravadi Ravi K, Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

IMPORTANCE

Health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19) are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, to our knowledge, there is no effective pharmacologic prophylaxis for individuals at risk.

OBJECTIVE

To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy.

DESIGN, SETTING, AND

PARTICIPANTS

This randomized, double-blind, placebo-controlled clinical trial (the Prevention and Treatment of COVID-19 With Hydroxychloroquine Study) was conducted at 2 tertiary urban hospitals, with enrollment from April 9, 2020, to July 14, 2020; follow-up ended August 4, 2020. The trial randomized 132 full-time, hospital-based HCWs (physicians, nurses, certified nursing assistants, emergency technicians, and respiratory therapists), of whom 125 were initially asymptomatic and had negative results for SARS-CoV-2 by nasopharyngeal swab. The trial was terminated early for futility before reaching a planned enrollment of 200 participants.

INTERVENTIONS: Hydroxychloroquine, 600 mg, daily, or size-matched placebo taken orally for 8 weeks.

MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of SARS-CoV-2 infection as determined by a nasopharyngeal swab during the 8 weeks of treatment. Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants.

RESULTS

Of the 132 randomized participants (median age, 33 years [range, 20-66 years]; 91 women [69%]), 125 (94.7%) were evaluable for the primary outcome. There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo (4 of 64 [6.3%] vs 4 of 61 [6.6%]; P > .99). Mild adverse events were more common in participants taking hydroxychloroquine compared with placebo (45% vs 26%; P = .04); rates of treatment discontinuation were similar in both arms (19% vs 16%; P = .81). The median change in QTc (baseline to 4-week evaluation) did not differ between arms (hydroxychloroquine: 4 milliseconds; 95% CI, -9 to 17; vs placebo: 3 milliseconds; 95% CI, -5 to 11; P = .98). Of the 8 participants with positive results for SARS-CoV-2 (6.4%), 6 developed viral symptoms; none required hospitalization, and all clinically recovered.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04329923.

Для цитирования: Abella Benjamin S, Jolkovsky Eliana L, Biney Barbara T, Uspal Julie E, Hyman Matthew C, Frank Ian, Hensley Scott E, Gill Saar, Vogl Dan T, Maillard Ivan, Babushok Daria V, Huang Alexander C, Nasta Sunita D, Walsh Jennifer C, Wiletyo E Paul, Gimotty Phyllis A, Milone Michael C, Amaravadi Ravi K, Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.. JAMA internal medicine. 2021. DOI: 10.1001/jamainternmed.2020.6319.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.